Diansheng Zhong Selected Research

Neoplasm Metastasis (Metastasis)

2/2024	Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared With Denosumab for Solid Tumor-Related Bone Metastases: A Randomized, Double-Blind, Phase 3 Equivalence Trial.
1/2023	Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studies.
1/2023	Retrospective study of EGFR-mutant lung adenocarcinoma with bone metastatic clinical features.
1/2022	STRN-ALK Fusion in Lung Adenocarcinoma with Brain Metastasis Responded Well to Ensartinib: A Case Report.
12/2021	The role of brain metastases in patients with pulmonary adenocarcinoma: a retrospective study.
1/2021	Difficult differential diagnosis of bladder pedicled masses about metastasis from non-small cell lung cancer: A case report.
12/2020	[Research Progress of Targeted Therapy for HER2 Gene  in Advanced Non-small Cell Lung Cancer].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Diansheng Zhong Research Topics

Disease

40	Neoplasms (Cancer) 02/2024 - 04/2008
35	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2023 - 11/2011
14	Lung Neoplasms (Lung Cancer) 03/2024 - 11/2011
8	Nausea 11/2023 - 10/2018
8	Vomiting 11/2023 - 10/2018
7	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 03/2024 - 04/2016
7	Neoplasm Metastasis (Metastasis) 02/2024 - 12/2020
4	Adenocarcinoma of Lung 01/2023 - 11/2017
3	Inflammation (Inflammations) 03/2024 - 01/2020
3	Carcinogenesis 06/2023 - 08/2009
3	Hemorrhage 02/2023 - 01/2014
3	Thrombocytopenia (Thrombopenia) 01/2023 - 01/2014
3	Disease Progression 11/2022 - 11/2017
3	Stomach Neoplasms (Stomach Cancer) 08/2022 - 01/2020
3	Breast Neoplasms (Breast Cancer) 01/2022 - 06/2006
3	Adenocarcinoma 12/2021 - 09/2008
2	Sarcoma (Soft Tissue Sarcoma) 10/2023 - 05/2020
2	Bites and Stings (Sting) 01/2023 - 01/2022
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022 - 01/2022
2	Neutropenia 01/2021 - 01/2017
2	Febrile Neutropenia 01/2021 - 01/2014
2	Malignant Pleural Effusion 06/2018 - 03/2015
2	Colorectal Neoplasms (Colorectal Cancer) 01/2018 - 09/2008
2	Prostatic Neoplasms (Prostate Cancer) 09/2008 - 08/2008
1	Malnutrition (Nutritional Deficiencies) 03/2024
1	Cancer Pain 11/2023
1	Ataxia Telangiectasia (Louis Bar Syndrome) 01/2023
1	Type 2 Diabetes Mellitus (MODY) 04/2022
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 04/2022
1	Diabetes Mellitus 01/2022
1	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 01/2022
1	Ovarian Neoplasms (Ovarian Cancer) 01/2022
1	Blister (Bulla) 01/2022

Drug/Important Bio-Agent (IBA)

12	ErbB Receptors (EGF Receptor)IBA 02/2023 - 12/2012
8	Tyrosine Kinase InhibitorsIBA 01/2023 - 06/2014
7	Cisplatin (Platino)FDA LinkGeneric 01/2023 - 11/2011
6	Proteins (Proteins, Gene)FDA Link 06/2023 - 08/2008
6	Immune Checkpoint InhibitorsIBA 01/2023 - 09/2019
5	Etoposide (VP 16)FDA LinkGeneric 03/2024 - 04/2016
5	Phosphotransferases (Kinase)IBA 01/2023 - 01/2016
4	AntiemeticsIBA 01/2023 - 03/2020
4	LigandsIBA 10/2022 - 12/2018
4	Death Domain ReceptorsIBA 10/2022 - 11/2011
4	DNA (Deoxyribonucleic Acid)IBA 06/2022 - 11/2011
4	Deoxyglucose (2 Deoxy D glucose)IBA 04/2021 - 04/2008
3	PlatinumIBA 03/2024 - 01/2017
3	fosaprepitant FDA Link 07/2023 - 03/2020
3	Biomarkers (Surrogate Marker)IBA 06/2023 - 01/2020
3	icotinibIBA 01/2023 - 01/2020
3	apatinibIBA 08/2022 - 01/2020
3	Antineoplastic Agents (Antineoplastics)IBA 06/2022 - 06/2013
3	Aprepitant (Emend)FDA Link 10/2020 - 10/2018
3	TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA 06/2013 - 11/2011
2	Therapeutic UsesIBA 06/2023 - 12/2021
2	aumolertinibIBA 02/2023 - 01/2023
2	Dexamethasone (Maxidex)FDA LinkGeneric 01/2023 - 10/2018
2	CrizotinibIBA 01/2023 - 01/2022
2	rezivertinibIBA 01/2023 - 11/2022
2	pembrolizumabIBA 01/2022 - 01/2022
2	osimertinibIBA 01/2021 - 01/2020
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 09/2019 - 08/2009
2	KinesinsIBA 01/2019 - 05/2014
2	Carboplatin (JM8)FDA LinkGeneric 01/2017 - 04/2016
2	Irinotecan (Camptosar)FDA LinkGeneric 01/2017 - 04/2016
2	Carbonic Anhydrase IXIBA 11/2015 - 01/2015
2	Messenger RNA (mRNA)IBA 12/2012 - 09/2008
1	Indicators and Reagents (Reagents)IBA 03/2024
1	tislelizumabIBA 03/2024
1	Denosumab FDA Link 02/2024
1	Biosimilar PharmaceuticalsIBA 02/2024
1	Opioid Analgesics (Opioids)IBA 11/2023
1	dabrafenibIBA 10/2023
1	trametinibIBA 10/2023
1	Palonosetron (Aloxi)FDA Link 07/2023
1	Bevacizumab (Avastin)FDA Link 02/2023
1	serum P-component (CIt)IBA 01/2023
1	InterferonsIBA 01/2023
1	anlotinibIBA 01/2023
1	Diphosphonates (Bisphosphonates)IBA 01/2023
1	Olanzapine (Zyprexa)FDA Link 01/2023
1	CreatinineIBA 01/2023
1	Ondansetron (Zofran)FDA LinkGeneric 01/2023
1	toripalimabIBA 01/2023
1	AZD1390IBA 01/2023
1	Immunoconjugates (Immunoconjugate)IBA 06/2022
1	durvalumabIBA 01/2022
1	Blood Glucose (Blood Sugar)IBA 01/2022
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022
1	Immune Checkpoint ProteinsIBA 01/2022
1	TabletsIBA 01/2022
1	Circulating Tumor DNAIBA 01/2022
1	ensartinibIBA 01/2022
1	SteroidsIBA 01/2022
1	A-Form DNA (A-DNA)IBA 01/2022
1	Niacinamide (Nicotinamide)FDA LinkGeneric 01/2022

Therapy/Procedure

26	Drug Therapy (Chemotherapy) 07/2023 - 04/2008
23	Therapeutics 01/2023 - 08/2009
6	Immunotherapy 01/2023 - 12/2018
2	Radiotherapy 12/2021 - 04/2008
1	Aftercare (After-Treatment) 02/2023